Summary & Overview
HCPCS C9027: Pembrolizumab Injection, 1 mg
HCPCS Level II code C9027 denotes a 1 mg unit of pembrolizumab, an immune checkpoint inhibitor used broadly in oncology. As a drug-specific HCPCS code, C9027 is used to report the administered quantity of pembrolizumab on medical claims and matters for coverage determinations, billing accuracy, and aggregate spend on high-cost oncology therapies nationwide. National payers and Medicare use HCPCS drug codes to reconcile drug acquisition, dosing, and reimbursement.
Key payers covered in this profile include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for pembrolizumab dosing and administration, what the HCPCS drug unit represents, and the types of settings where claims commonly originate. The analysis highlights reimbursement benchmarking, common billing considerations tied to unitization of expensive oncology biologics, and notes on policy or coding updates when available.
This summary is intended to inform revenue cycle, pharmacy, and clinical operations teams about the implications of using HCPCS Level II code C9027 on claims, and to help payers and providers align on coding for accurate payment and utilization reporting.
Billing Code Overview
HCPCS Level II code C9027 describes Injection, pembrolizumab, 1 mg. This code represents a billed unit of the monoclonal antibody pembrolizumab administered by injection, with each unit corresponding to 1 mg of the drug.
Service Type: Drug administration / oncology biologic therapy
Typical Site of Service: Hospital outpatient infusion center, physician office infusion suite, or ambulatory infusion center, reflecting settings where intravenous or subcutaneous oncology biologic injections are commonly delivered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with metastatic non-small cell lung cancer (NSCLC) scheduled to receive systemic immunotherapy in an outpatient infusion center. The patient arrives for a planned intravenous administration of pembrolizumab dosed per weight or fixed-dose equivalent; billing is recorded using C9027 to capture the drug at 1 mg units. The clinical workflow includes verification of identity, review of recent labs (complete blood count, liver function tests), assessment for immune-related adverse events, consent confirmation, and pre-medication review. The oncology RN prepares pembrolizumab from the pharmacy (aseptic technique), confirms dose calculation with the oncology pharmacist, and administers the infusion via peripheral or central venous access over the recommended infusion time while monitoring vital signs. Post-infusion monitoring for infusion reactions and documentation of lot number, NDC, and administered mg billed via C9027 ensues. Prior authorization and medical necessity documentation are obtained from payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare when required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | When a separate, distinct service or procedure is performed that is not normally reported together with another service |